MorphoSys AG (MorphoSys AG) Debt-to-Equity

: 12.97 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

MorphoSys AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $15.3 Mil. MorphoSys AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $678.2 Mil. MorphoSys AG's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $53.5 Mil. MorphoSys AG's debt to equity for the quarter that ended in Dec. 2023 was 12.97.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for MorphoSys AG's Debt-to-Equity or its related term are showing as below:

MOR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.31 Max: 12.97
Current: 12.97

During the past 13 years, the highest Debt-to-Equity Ratio of MorphoSys AG was 12.97. The lowest was 0.00. And the median was 0.31.

MOR's Debt-to-Equity is ranked worse than
99.63% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs MOR: 12.97

MorphoSys AG Debt-to-Equity Historical Data

The historical data trend for MorphoSys AG's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.11

0.51

1.33

4.44

12.97

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																4.44	2.90	8.88	N/A	12.97

Competitive Comparison

For the Biotechnology subindustry, MorphoSys AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MorphoSys AG Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, MorphoSys AG's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's Debt-to-Equity falls into.

MorphoSys AG Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

MorphoSys AG's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(15.323	+	678.17)	/	53.489
	=	12.97

MorphoSys AG's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(15.323	+	678.17)	/	53.489
	=	12.97

MorphoSys AG (NAS:MOR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

MorphoSys AG Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (MorphoSys AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (NAS:MOR) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MPSYF:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany MOR:Austria

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.